Drugs & Targets FDA approves Braftovi + Mektovi combination in a melanoma indication June 29, 2018Vol.44 No.26
Drugs & Targets Kymab, Roche agree to evaluate KY1044, anti-PD-L1 immunotherapy in solid tumors June 29, 2018Vol.44 No.26
Drugs & Targets FDA grants orphan drug designation for CPI-613 for Burkitt lymphoma June 29, 2018Vol.44 No.26
Clinical Roundup Lynparza delays disease progression in phase III trial in first-line ovarian cancer June 29, 2018Vol.44 No.26
Clinical Roundup Tecentriq + chemo increase OS, PFS in untreated extensive stage small cell lung cancer June 29, 2018Vol.44 No.26
Clinical Roundup Trifluridine and tipiracil meet OS endpoint in phase III trial June 29, 2018Vol.44 No.26
Clinical Roundup ONS develops hazardous drugs safe handling toolkit for oncology nurses June 29, 2018Vol.44 No.26
In Brief Case Comprehensive Cancer Center earns “exceptional” rating, $31.9M in NCI grants June 29, 2018Vol.44 No.26
In Brief UPMC and Pitt open genome center for precision medicine, immunotherapy June 29, 2018Vol.44 No.26
